Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
May 24, 2018
- RT002 achieved high response rate, long-lasting effect across all treatment groups and doses - - RT002 appeared generally safe and well-tolerated through Week 36 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company d...
May 15, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the UBS Global Healthcare Conference in New York, NY. ...
May 9, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its management team with the appointments of Conor Gallagher, Ph.D., as Head of Medical Affairs,...
May 8, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the first quarter ended March 31, 2018. Recent Company Highlights and Upcomi...
May 1, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its executive leadership team with the appointment of Caryn McDowell as Senior Vice President, ...
Apr 25, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced oral and ePoster presentations of clinical data from the company's two pivotal SAKURA Phase 3 trials of ...
Apr 24, 2018
-Conference Call Scheduled for Tuesday, May 8, 2018 at 4:30pm ET- NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will rel...
Apr 19, 2018
- Lead product for treatment of glabellar lines on track to report SAKURA Phase 3 open-label safety results in second half of 2018 - - Initiating Phase 3 pivotal trial for cervical dystonia in current quarter - - Company to add RT002 clinical programs in adult upper limb s...
Apr 2, 2018
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced the appointments of Dustin Sjuts as Vice President of Strategy and Sales, Aesthetic and Therapeutic; ...
Mar 26, 2018
-Webcast to begin at 12:00pm ET- NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will host a live web...
Page:
1
... NextLast
= add release to Briefcase
Shareholder Tools